Search Results

Co-Diagnostics, Inc. announced that the Company has completed its first U.S. Food and Drug Administration application for 510 clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter use.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced financial results for the quarter ended March 31, 2024.

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close.

Co-Diagnostics, Inc. announced that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, England.

Co-Diagnostics, Inc. today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO).